Stargardt disease is the most common form of inherited macular degeneration in young people. It damages the macula, the small central area of the retina responsible for sharp, detailed vision, and it typically appears in late childhood to early adulthood. In the United States, it affects roughly 10 to 12.5 out of every 100,000 people.
Unlike age-related macular degeneration, which develops in older adults, Stargardt disease is genetic. Most people inherit it in an autosomal recessive pattern, meaning both parents carry a copy of the faulty gene without having any symptoms themselves. A rarer, autosomal dominant form also exists but is far less common.
What Happens Inside the Eye
Stargardt disease starts with a problem in a single gene called ABCA4. This gene provides instructions for building a transporter protein that sits inside the light-sensing cells of your retina, both rods and cones. Every time light hits these cells, a byproduct of vitamin A is released. Normally, the ABCA4 transporter clears that byproduct away so the cells can reset and respond to light again.
When the ABCA4 transporter doesn’t work properly, the vitamin A byproduct accumulates and forms a toxic compound. This compound builds up in the retinal pigment epithelium (RPE), a thin layer of cells directly behind the retina that nourishes and supports the light-sensing cells. Over time, the toxic buildup poisons RPE cells in several ways: it makes them vulnerable to blue-light damage, interferes with their ability to break down waste, triggers cell death signals from mitochondria, and destabilizes cell membranes. As RPE cells die, the photoreceptors they support also degenerate, and central vision gradually fades.
Early Symptoms and How Vision Changes
The first sign most people notice is blurry or slightly distorted central vision. You might have trouble reading small print, recognizing faces at a distance, or seeing fine detail that used to be easy to make out. Some people also develop difficulty seeing in low light, which can make navigating dimly lit rooms or driving at dusk noticeably harder. Impaired color vision is another common early symptom.
The speed of vision loss varies. A study tracking people with late-onset Stargardt disease found that, on average, it took about 3 years from the start of symptoms to reach mildly reduced vision, roughly 10 years to reach moderate vision loss, and about 11 years to reach 20/200, the threshold for legal blindness in the United States. The area of RPE damage expands by about 0.22 millimeters per year. These numbers represent averages, and individual experiences can differ substantially depending on the specific genetic mutations involved. Peripheral vision is typically preserved, so complete blindness is rare.
How Stargardt Disease Is Diagnosed
Eye doctors use a combination of imaging and functional tests to confirm Stargardt disease. One of the most informative tools is fundus autofluorescence (FAF), a specialized photograph that reveals the pattern of toxic buildup in the RPE. In early stages, the image may show a small area of damage confined to the center of the macula with an otherwise normal background. In more advanced cases, the damage spreads outward, with scattered patches of RPE loss extending beyond the central retina.
Electroretinography (ERG), which measures the electrical responses of retinal cells to light, is considered the gold standard for assessing how much retinal function remains. Results fall into a spectrum: some people show damage limited to central vision while their peripheral retinal function stays intact, while others show broader dysfunction affecting both cone cells (responsible for daylight and color vision) and rod cells (responsible for low-light vision). Genetic testing can confirm ABCA4 mutations and is increasingly used alongside imaging to guide prognosis.
Protecting Your Eyes Day to Day
Because the toxic compound that builds up in Stargardt disease is activated by light, particularly blue and ultraviolet wavelengths, protecting your eyes from these wavelengths is one of the most practical things you can do. UV exposure cannot reverse damage already done, but limiting it may help slow further harm. Wrap-around sunglasses or close-fitting frames with blue-blocking lenses offer the most coverage. A wide-brimmed hat adds another layer of protection. If you wear prescription glasses, blue-blocking filters can be built into the lenses.
Glare management makes a real difference in daily comfort. If white paper is hard to look at, a yellow transparent overlay or yellow-tinted anti-glare glasses can help. For computer use, reducing screen brightness or switching to dark mode eases strain. At home, keeping lighting bright but even, with shaded lamps positioned so light doesn’t shine directly into your eyes, reduces the constant squinting that comes with uneven illumination. For driving, a clean windshield (inside and out) and anti-reflection coated lenses cut down on headlight glare at night.
The Question of Vitamin A
Since the disease involves a breakdown in how the retina processes vitamin A, a logical concern is whether dietary vitamin A makes things worse. Many eye care organizations recommend that people with Stargardt disease avoid high-dose vitamin A supplements. The reasoning is straightforward: more vitamin A entering the retina means more of the toxic byproduct the faulty transporter can’t clear.
The actual clinical evidence, however, is limited. Animal studies using mice with the same genetic defect showed no measurable difference in retinal function between high and low vitamin A levels. In humans, one cross-sectional study found better visual function in patients with lower vitamin A intake, but a separate prospective study found no link between supplementation and visual acuity. The recommendation to avoid supplements rests more on the biological logic than on strong clinical proof. Most experts advise eating a normal, balanced diet without restricting vitamin A from food, but skipping standalone vitamin A supplements or multivitamins with high vitamin A content.
Living With Stargardt Disease
Because central vision is affected while peripheral vision remains largely intact, most people with Stargardt disease continue to live independently. Low-vision aids make a significant practical difference. Magnifying devices, large-print settings on phones and computers, screen readers, and high-contrast text all help bridge the gap left by declining central sharpness. Many people learn eccentric viewing, a technique where you train yourself to use a part of the retina just outside the damaged macula to focus on objects.
The condition does affect activities that rely heavily on fine central detail. Reading, driving, and recognizing faces at a distance become progressively harder. In many cases, people eventually qualify for low-vision services and assistive technology programs that can provide tailored support. Since Stargardt disease is diagnosed young, connecting with these resources early, rather than waiting until vision loss becomes severe, gives people more time to adapt and build strategies that fit their daily lives.